GSK closing Stiefel plants
This article was originally published in The Rose Sheet
Executive Summary
GlaxoSmithKline plans to grow its dermatology sales through its recently acquired Stiefel Laboratories business without the firm's manufacturing facilities in New York and Ireland. In a Nov. 13 e-mail, a Stiefel spokeswoman said GSK's Global Manufacturing & Supply unit will close the Oak Hill, N.Y., and Sligo, Ireland facilities by the end of 2012. Production will continue at the sites until the products are transferred to other facilities, including contract manufacturers. Stiefel said 263 employees work at the Oak Hill plant and 250 at the Sligo site. When GSK acquired Stiefel for $2.9 bil. in cash in April, it said it expected to more than double its dermatology sales to $1.5 billion by creating a global specialist business across Rx and OTC products (1"The Rose Sheet" April 27, 2009)
You may also be interested in...
GSK Gains Foothold In U.S. Skin Care With Stiefel Deal
GlaxoSmithKline will more than double its dermatology sales to $1.5 billion with the acquisition of Stiefel Laboratories, a move that provides GSK a foothold in the U.S. market for nonprescription skin-care products
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.